New hope for bile duct cancer: Four-Drug cocktail trial launches
NCT ID NCT05849480
First seen Jan 27, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tests a new drug (CDX-1140) plus three standard cancer drugs (capecitabine, oxaliplatin, and Keytruda) in people with advanced bile duct cancer that has stopped responding to treatment. About 60 adults will receive the drugs in 21-day cycles for up to 2 years, with follow-up for 3 more years. The goal is to find a safe dose and see if the combination can shrink tumors or delay cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.